Biotech Values

[swampboots]

DEW : Regarding all the fine points assumed (for agrument sake) in this older message of yours.
"The revelation that GENR is submitting the phase 1/2 Squalamine data to an independent review panel makes me think this was requested by one or more prospective partners. In other words, the Squalamine data was so good that prospective partners wanted to be sure it was real!"

My opinion is that mere confirmation of these results (with all the safety and dosage trimmings) would make the protocol (refered to in the above quote) worthy of immediate universal application. That is, the improvments/containments even for as short as 2 months must be worth thousands per course of treatment per patient now at current trial end points. Holding a patient's vision constant while multiple new applications are being reveiwed seems too compelling to dismiss. But the point is not a narrative about challenging the process. The point I am making is that the above referenced results once confirmed, (as long as it can logically take), before cash burn, is likely to already be reflected in the current stock price of GENR without any other new progressive data revelations likely to be validated.